可穿戴抗重力辅助疗法未改善慢性卒中手臂功能:一项随机试点试验
结果显示两组在ARAT、FMA-UE和WMFT上无显著差异,但治疗组在干预后Box and Blocks评分有改善(效应量=2.1,P=.04)。ExoNET抗重力疗法安全可行,未限制关节活动度。
要点
- ExoNET抗重力疗法安全可行,未限制关节活动度。
- 两组在ARAT、FMA-UE和WMFT上无显著差异。
- 治疗组干预后Box and Blocks评分改善(效应量=2.1,P=.04)。
核心结论
- ExoNET抗重力疗法对慢性卒中患者安全可行,但未在主要临床指标上显示优于对照组的疗效。
- 治疗组在干预后粗大手动灵巧性(Box and Blocks)有改善,需进一步研究验证。
研究设计与样本
- 两组均接受6次45分钟作业治疗,由盲法评估者在基线、干预后和6周随访时评估临床结局。
主要发现
- 治疗组与对照组在Action Research Arm Test、Fugl-Meyer Upper Extremity和Wolf Motor Function Test评分上无显著组间差异。
- 治疗组在干预后Box and Blocks评分改善,效应量=2.1,P=.04。
- 自由探索时肌肉活动显著降低,效应量=-7.12%,P<.005,但无纵向动力学或运动学趋势。
- 受试者反馈对抗重力疗法总体持积极看法。
关键数值与推荐
- Box and Blocks评分改善:效应量=2.1,P=.04(治疗组干预后)。
- 肌肉活动降低:效应量=-7.12%,P<.005(自由探索时)。
临床怎么用
- ExoNET抗重力疗法可作为慢性卒中康复的安全可行选项,但不应期望其主要临床指标显著优于常规治疗。
- 可关注其对粗大手动灵巧性的潜在改善,但需更多研究验证。
局限性
- 未发现纵向动力学或运动学趋势,疗效机制尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundGravity confounds arm movement ability in post-stroke hemiparesis. Reducing its influence allows effective practice leading to recovery. Yet, there is a scarcity of wearable devices suitable for personalized use across diverse therapeutic activities in the clinic.ObjectiveIn this pilot study, we investigated the safety, feasibility, and efficacy of anti-gravity therapy using the ExoNET device in post-stroke participants.MethodsTwenty chronic stroke survivors underwent six, 45-minute occupational therapy sessions while wearing the ExoNET, randomized into either the treatment (ExoNET tuned to gravity-support) or control group (ExoNET tuned to slack condition). Clinical outcomes were evaluated by a blinded-rater at baseline, post, and 6-week follow-up sessions. Kinetic, kinematic, and patient experience outcomes were also assessed.ResultsNo significant effects were found between the treatment and control groups for Action Research Arm Test, Fugl-Meyer Upper Extremity, and Wolf Motor Function Test scores though the treatment group showed an improvement in Box and Blocks scores in the post-intervention session (effect size = 2.1, P = .04). Direct kinetic effects revealed a significant reduction in muscle activity during free exploration with an effect size of (-7.12%, P < .005) but no longitudinal kinetic or kinematic trends. Subject feedback suggested a generally positive perception of the anti-gravity therapy.ConclusionsAnti-gravity therapy with the ExoNET is a safe and feasible treatment for post-stroke rehabilitation. The device provided anti-gravity forces, did not encumber range of motion, and clinical metrics of anti-gravity therapy demonstrated improvements in gross manual dexterity. Further research is required to explore potential benefits in broader clinical metrics.Trial Registration:This study was registered at ClinicalTrials.gov (ID# NCT05180812).
引用
- Celian C, Ryali P, Wilson V, et al. A Wearable Anti-Gravity Supplement to Therapy Does Not Improve Arm Function in Chronic Stroke: A Randomized Pilot Trial. Neurorehabil Neural Repair. 2025. PMID: 40537460. doi:10.1177/15459683251338792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。